BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of ILS 152.38 million. The enterprise value is 119.23 million.

Market Cap	152.38M
Enterprise Value	119.23M

Important Dates

The next estimated earnings date is Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 1.20 billion shares outstanding. The number of shares has increased by 22.24% in one year.

Shares Outstanding	1.20B
Shares Change (YoY)	+22.24%
Shares Change (QoQ)	+10.21%
Owned by Insiders (%)	0.36%
Owned by Institutions (%)	5.53%
Float	1.09B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.12
PB Ratio	2.89
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.05
EV / Sales	1.86
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.04

Financial Position

The company has a current ratio of 1.61, with a Debt / Equity ratio of 2.24.

Current Ratio	1.61
Quick Ratio	1.44
Debt / Equity	2.24
Debt / EBITDA	n/a
Debt / FCF	-1.03
Interest Coverage	-12.03

Financial Efficiency

Return on equity (ROE) is -171.94% and return on invested capital (ROIC) is -54.52%.

Return on Equity (ROE)	-171.94%
Return on Assets (ROA)	-35.23%
Return on Capital (ROIC)	-54.52%
Revenue Per Employee	812,499
Profits Per Employee	-1.44M
Employee Count	79
Asset Turnover	0.28
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -68.65% in the last 52 weeks. The beta is 0.80, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	-68.65%
50-Day Moving Average	16.53
200-Day Moving Average	24.97
Relative Strength Index (RSI)	22.80
Average Volume (20 Days)	702,486

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BioLineRx had revenue of ILS 64.19 million and -113.40 million in losses. Loss per share was -0.12.

Revenue	64.19M
Gross Profit	41.43M
Operating Income	-131.08M
Pretax Income	-113.40M
Net Income	-113.40M
EBITDA	-124.55M
EBIT	-131.08M
Loss Per Share	-0.12

Full Income Statement

Balance Sheet

The company has 150.83 million in cash and 117.68 million in debt, giving a net cash position of 33.15 million or 0.03 per share.

Cash & Cash Equivalents	150.83M
Total Debt	117.68M
Net Cash	33.15M
Net Cash Per Share	0.03
Equity (Book Value)	52.64M
Book Value Per Share	0.04
Working Capital	70.01M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -114.26 million and capital expenditures -286,148, giving a free cash flow of -114.55 million.

Operating Cash Flow	-114.26M
Capital Expenditures	-286,148
Free Cash Flow	-114.55M
FCF Per Share	-0.10

Full Cash Flow Statement

Margins

Gross margin is 64.55%, with operating and profit margins of -204.22% and -176.67%.

Gross Margin	64.55%
Operating Margin	-204.22%
Pretax Margin	-176.67%
Profit Margin	-176.67%
EBITDA Margin	-194.04%
EBIT Margin	-204.22%
FCF Margin	-178.46%

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.24%
Shareholder Yield	-22.24%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on June 7, 2015. It was a reverse split with a ratio of 0.1.

Last Split Date	Jun 7, 2015
Split Type	Reverse
Split Ratio	0.1

Scores

BioLineRx has an Altman Z-Score of -8.56. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.56
Piotroski F-Score	n/a